Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on the naturally occurring tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which is a fragment of immunoglobulin G and plays a role in immune modulation. Selank extends tuftsin with three additional amino acids (Pro-Gly-Pro) to improve metabolic stability and enhance its neurotropic properties. The result is a peptide with both immunomodulatory and anxiolytic activity.

Selank has been approved in Russia as a treatment for anxiety and related conditions, where it has been available as a nasal spray since the mid-2000s. Its anxiolytic mechanism differs fundamentally from benzodiazepines — rather than acting on GABA receptors, Selank appears to modulate the balance of neurotransmitter systems, including serotonin, norepinephrine, and dopamine metabolism. Research has shown it can influence the expression of brain-derived neurotrophic factor (BDNF) and enkephalin genes, suggesting a modulatory role in neuroplasticity and stress response.

One of Selank's distinguishing features is its reported absence of sedation, cognitive impairment, and addictive potential — common drawbacks of traditional anxiolytic medications. Russian clinical studies have reported reductions in anxiety comparable to benzodiazepines but without the drowsiness, tolerance development, or withdrawal symptoms. Users often report improvements in mental clarity, focus, and emotional stability alongside anxiolytic effects.

Beyond its neurological applications, Selank has demonstrated immunomodulatory activity consistent with its tuftsin-derived structure. Research has shown it can modulate cytokine expression, influence T-cell function, and may have antiviral properties. This dual anxiolytic-immunomodulatory profile makes Selank a unique peptide that bridges the gap between neurological and immune system support. However, most clinical data comes from Russian studies, and large Western clinical trials are lacking.